Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming... The post Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing appeared first on Montreal Gazette .

Original source: Montreal Gazette